If you need more lookups,
subscriptions start at $34 USD/month.
Chris Cann Location
Southampton, PA, US
Chris Cann Work
2021 -now Chief Operating Officer @
2018 -2021 VP, NASH Strategic Marketing @
2015 -2018 VP Marketing @
2014 -2015 Head, SaxaDapa Franchise, GPPS @
2012 -2014 VP, Global Commercial Lead, Amylin Integration and BMS Diabetes Divestiture @
2009 -2011 VP, Global Brand Lead, Onglyza Franchise, Global Commercialization @
2006 -2008 VP, Disease Area Lead, Metabolic Franchise @
2004 -2005 VP, Diabetes Marketing, US Pharmaceuticals @
2001 -2004 Senior Director, CV Marketing, US Pharmaceuticals @
1998 -2000 Senior Director, CV and Metabolic Franchise, International Region @
1996 -1997 Franchise Director, Cholesterol and Head, Payor Marketing @
1994 -1996 Regional Business Director @
1993 -1994 National Sales Manager, Specialty and Institutions Division @
1989 -1992 Marketing, CV and Metabolic Franchise @
1987 -1989 Sales Representative @
Chris Cann Education
Coventry University
BSc (Biology)
1983-1987
Chris Cann Skills
Leadership
Management
Microsoft Excel
New Business Development
Global Alliance Management
Clinical Trials
CRO
Cardiology
Clinical Research
Biotechnology
Regulatory Affairs
English
Healthcare
Strategy
Sales Effectiveness
Oncology
Marketing
Strategic Leadership
Drug Development
Cross Functional Team Leadership
Clinical Development
Diabetes
Product Launch
Pharmaceutical Industry
Pharmaceutical Sales
Market Access
Therapeutic Areas
Chris Cann Summary
Chris Cann, based in Southampton, PA, US, is currently a Chief Operating Officer at Zydus Therapeutics. Chris Cann brings experience from previous roles at Intercept Pharmaceuticals, Sanofi, AstraZeneca and Bristol-Myers Squibb. Chris Cann holds a 1983 - 1987 BSc in Biology @ Coventry University. With a robust skill set that includes Leadership, Management, Microsoft Excel, New Business Development, Global Alliance Management and more. Chris Cann has 3 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Chris Cann?
Find contact details for 700 million professionals.